FDA Grants Breakthrough Device Designation to Amprion’s PMCA Early Detection Tool

FDA Grants Breakthrough Device Designation to Amprion’s PMCA Early Detection Tool
The U.S Food and Drug Administration (FDA) has granted a Breakthrough Device designation to Amprion’s proprietary technology, Protein Misfolding Cyclic Amplification (PMCA) — a device that holds the potential to diagnose Parkinson’s disease at a much earlier stage than current diagnostic methods. If approved by the FDA, Amprion anticipates a market roll-out for PMCA tests as an early detection tool ... read more
Source: Parkinson’s News TodayPublished on 2019-05-28By Iqra Mumal